Peregrine Capital Management LLC decreased its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 3.2% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 1,223,278 shares of the biotechnology company’s stock after selling 41,039 shares during the period. Peregrine Capital Management LLC owned about 0.77% of Ironwood Pharmaceuticals worth $12,624,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the company. First Manhattan Co. grew its holdings in shares of Ironwood Pharmaceuticals by 7.2% in the first quarter. First Manhattan Co. now owns 14,925 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 1,000 shares during the last quarter. Profund Advisors LLC grew its holdings in shares of Ironwood Pharmaceuticals by 21.7% in the fourth quarter. Profund Advisors LLC now owns 15,558 shares of the biotechnology company’s stock worth $207,000 after purchasing an additional 2,777 shares during the last quarter. Strs Ohio bought a new position in shares of Ironwood Pharmaceuticals in the first quarter worth approximately $29,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Ironwood Pharmaceuticals by 21.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 19,285 shares of the biotechnology company’s stock worth $199,000 after purchasing an additional 3,441 shares during the last quarter. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC grew its holdings in shares of Ironwood Pharmaceuticals by 21.2% in the second quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 20,610 shares of the biotechnology company’s stock worth $212,000 after purchasing an additional 3,600 shares during the last quarter.

Several brokerages have recently issued reports on IRWD. TheStreet cut shares of Ironwood Pharmaceuticals from a “c” rating to a “d+” rating in a report on Monday, May 11th. Wells Fargo & Co cut their price target on shares of Ironwood Pharmaceuticals from $16.00 to $15.00 and set an “overweight” rating on the stock in a report on Thursday, April 30th. Northland Securities assumed coverage on shares of Ironwood Pharmaceuticals in a report on Wednesday, June 17th. They issued an “outperform” rating and a $14.00 price target on the stock. Morgan Stanley cut their price target on shares of Ironwood Pharmaceuticals from $11.00 to $10.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 15th. Finally, HC Wainwright cut their price target on shares of Ironwood Pharmaceuticals from $13.00 to $11.00 and set a “neutral” rating on the stock in a report on Monday, May 11th. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $12.00.

NASDAQ IRWD traded down $0.25 during trading hours on Friday, hitting $9.17. The company’s stock had a trading volume of 4,678,652 shares, compared to its average volume of 1,819,141. Ironwood Pharmaceuticals, Inc. has a 12 month low of $7.91 and a 12 month high of $14.10. The company’s 50 day simple moving average is $9.88 and its two-hundred day simple moving average is $10.73. The company has a market cap of $1.50 billion, a P/E ratio of 17.30 and a beta of 1.44.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.05 by ($0.01). The business had revenue of $79.94 million during the quarter, compared to the consensus estimate of $78.62 million. Ironwood Pharmaceuticals had a negative return on equity of 96.13% and a net margin of 19.14%. Ironwood Pharmaceuticals’s quarterly revenue was up 16.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.26) earnings per share. On average, equities analysts predict that Ironwood Pharmaceuticals, Inc. will post 0.4 EPS for the current year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD.

Further Reading: How is the S&P 500 index different from the DJIA?

Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.